{
  "docId": "019de076-a4b3-719a-94d2-ca29be1b4679",
  "docSlug": "0f14c676100503df3bb87c658cc9d332",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 26,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a four-column layout to summarize the company's value proposition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-a4b3-719a-94d2-ca29be1b4679/3",
  "deckHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679",
  "deckJsonHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679.json",
  "deckAnchorHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.22,
        "x": 0.75,
        "y": 0.18
      },
      "kind": "list",
      "text": "Platform-Validating Partnership: Collaboration with AstraZeneca leveraging Fusion's platform and deep expertise",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "007598a7-98ba-49bc-9076-499c9afd9e90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.22,
        "x": 0.27,
        "y": 0.18
      },
      "kind": "list",
      "text": "Actinium & Manufacturing Advantages: Early investments in 225Ac & a fully operational manufacturing facility designed to meet supply demands provides strategic advantage",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2064670c-633b-49cd-bab3-d66c1146f4aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.22,
        "x": 0.51,
        "y": 0.18
      },
      "kind": "list",
      "text": "Diversified Clinical-Stage Pipeline: Novel targeted alpha therapies (TATs) including next-gen ADCs to move the field beyond NETs and prostate cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ef10357-0c47-4b58-b03d-0500cb5d2df7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.22,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "list",
      "text": "Lead Program AcPSMA in Phase 2/3: Positioned to be first Ac-PSMA targeted radiotherapy to market for treatment of post-lutetium mCRPC, if approved; achieved alignment with FDA on potential registration pathway",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70daaebd-0c12-4f20-b971-98f1c2050135",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.86
      },
      "kind": "title",
      "text": "Creating cancer therapies by harnessing the potency and precision of targeted alpha therapies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef22c9e2-2aa4-441f-8787-e3d8d712d27c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Fusion is a Leader in the Radiopharmaceutical Space",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac4391c4-5b73-4ece-81da-ee81da88413a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "f6ec9f62-6bd2-4b47-ba62-0bff6b7319ae",
      "evidence": "The content is tailored to an audience interested in pharmaceuticals and radiopharmaceuticals, indicating an understanding of the audience.",
      "confidence": 0.7
    },
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "d67c3767-19ac-4834-9476-f695950d0eff",
      "evidence": "This slide serves as an executive summary, highlighting key points about Fusion's position in the radiopharmaceutical space.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 3,
      "beatId": "554bdf6e-c16b-49c5-afba-493e028c18d3",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents an overview of the radiopharmaceutical space and the potential of FPI-2265",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}